Three storylines are shaping the plaintiff bar's strategic calendar as the fourth quarter opens: the GLP-1 receptor agonist MDL is approaching trial-ready status on its first injury track; PFAS/AFFF personal injury bellwethers are set for November in South Carolina; and New York's sweeping 2026 auto tort reform is producing concrete changes in how carriers value claims and how plaintiff firms pick venues. Here is where each of those dockets stands and what practice groups need to track.
GLP-1 MDL: From Intake Surge to Daubert Crucible
The federal Glucagon-Like Peptide-1 receptor agonist MDL in the Eastern District of Pennsylvania crossed 4,000 pending cases in September 2026, driven by continued intake on gastroparesis claims and accelerating filings on the NAION (non-arteritic anterior ischemic optic neuropathy) injury track. Judge Karen Marston's July 2026 case management order directed early discovery in the NAION litigation to focus on cross-cutting causation issues, which signals the court is building toward a Daubert hearing on general causation before any bellwether is calendared.
The science story matters. A Harvard study published in JAMA Ophthalmology reported a four-to-seven-fold elevated NAION risk in GLP-1 users, a number significant enough that Novo Nordisk and Eli Lilly face a serious general-causation argument if it survives Daubert scrutiny. Defense experts are expected to contest dose-response data and argue that the association reflects confounding from the underlying conditions, not the drug itself. The outcome of the causation hearing will determine whether the NAION track moves toward bellwether selection or collapses into dismissals.
On the gastroparesis track, general-causation expert discovery is still open. The central contested issue is whether GLP-1 drugs cause clinically significant gastroparesis as opposed to the gastric emptying delay that is a known, labeled pharmacological effect of the drug class. That line-drawing exercise will define which plaintiff population has a viable claim and which does not. Firms holding large inventories of GLP-1 gastroparesis cases should be monitoring the expert report schedules closely; the Daubert ruling on that track could arrive before the end of the year.
PFAS Personal Injury: Bellwether November, Settlement Pressure Building
The AFFF firefighting foam personal injury MDL in the District of South Carolina now carries more than 15,000 pending cases according to the Judicial Panel's July 2026 report. Personal injury bellwether trials are calendared for November 2026, which means that for the first time, a jury will assign a dollar value to the specific cancer claims that plaintiff counsel has been building for years.
The court has focused the personal injury track on six cancer categories with the strongest causation evidence: kidney cancer, testicular cancer, thyroid disease, thyroid cancer, ulcerative colitis, and liver cancer. Military firefighters and airport crash rescue workers who used AFFF for decades are the core plaintiff population. Defendants include 3M, DuPont, and a range of chemical manufacturers and formulators. 3M's prior municipal water settlement, while substantial, explicitly excluded personal injury claims, leaving the individual cancer track unresolved.
The November bellwether outcome will set informal settlement values for the broader inventory. Plaintiff firms that have been holding cases pending that valuation signal should have their medical chronologies, expert designations, and damages profiles complete before November. Bellwether posture on both sides will be shaped heavily by the causation expert reports already exchanged; the trial is not a de novo event but a public readout of arguments that have been in preparation for two-plus years.
New York Auto Reform: The First Six Months of Data
New York's FY2027 budget enacted in May 2026 converted the state from pure comparative negligence to a modified comparative fault bar specifically for motor vehicle accident claims governed by Insurance Law Article 51. The reform, which took effect immediately on enactment, has produced measurable early effects on how carriers approach auto files.
The key changes: a plaintiff whose fault exceeds 50 percent cannot recover in a covered auto accident. Juries must now decide fault sequencing before reaching the serious injury threshold. The 90/180 serious injury category was eliminated. A new $100,000 noneconomic damages cap applies to drivers who were uninsured, impaired, or committing a felony at the time of the accident. Pure comparative fault still operates outside Article 51, meaning premises cases, construction cases, and defective products claims are unaffected.
For plaintiff counsel, the immediate strategic consequence is rigorous comparative fault analysis at intake. Cases where the plaintiff's own conduct is arguable at more than 50 percent now carry a litigation-ending risk that did not exist before May. Intersection and rear-end cases where surveillance is absent and witness accounts conflict require more diligence at the pre-suit stage. The elimination of the 90/180 category has tightened the serious injury gateway, and carriers are already using that change as a basis for early coverage denials on soft-tissue files.
Defense carriers have been aggressive on the fault sequencing instruction, pushing for that determination to be made before the jury hears the medical evidence. Plaintiff counsel's response is to build the liability record with enough objective evidence that the fault question is not genuinely close, keeping the jury's attention on damages rather than on threshold battles.
Texas Tort Reform 2026: What Passed and What Did Not
Texas completed its 2026 legislative session with a more limited tort reform package than defense interests had sought. The legislature did not enact a broad noneconomic damages cap for general civil cases, but it did tighten the paid-versus-billed medical damages rule, strengthening the existing framework under which plaintiffs may only recover the amounts actually paid by or on behalf of them for medical care, not the full billed amount. That change reinforces the existing Haygood framework and reduces the gap between billed and paid medical damages in lien-heavy cases.
Texas also amended its proportionate responsibility statute to add a new evidentiary standard for third-party designation, requiring that designated parties be identified with enough specificity to allow a meaningful jury determination of their responsibility. Defense attempts to designate phantom tortfeasors based on speculative theories now face a higher hurdle in Texas trial courts. Plaintiff firms handling Texas cases with multiple potential defendants should update their third-party designation defense protocols accordingly.
Nuclear Verdict Trend Continues Upward
Analysis of 2026 verdict data through September shows that the nuclear verdict trend that defined the previous several years has not plateaued. Jury awards exceeding $10 million rose approximately 52 percent year-over-year in 2024, a pace that appears to have continued into 2025 and 2026. The average verdict in catastrophic personal injury cases, according to aggregated data from verdict tracking services, now exceeds $51 million, though that figure is heavily influenced by outlier results including a $644.8 million premises verdict in Florida and a $603 million counterfeit airbag wrongful death award.
The pattern that plaintiff practitioners should note: large verdicts are no longer concentrated in a small number of plaintiff-friendly jurisdictions. Florida, which enacted significant tort reforms in 2023, is still producing nuclear verdicts in premises and products cases. Georgia, despite SB 68's bifurcation requirement, produced multiple eight-figure verdicts through the first three quarters of 2026. New York's reform targets the auto docket, not premises or products, leaving those categories fully exposed to the state's historically plaintiff-favorable jury pools.
Mass Tort Calendar: What to Watch in Q4
Beyond PFAS, several mass tort dockets are at inflection points heading into the fourth quarter. The hernia mesh MDL in the District of Connecticut has approximately 23,000 cases pending and court-appointed special masters are running an intensive settlement process for unresolved claims. Firms with hernia mesh inventory that have not engaged that process should do so now; the settlement window may not remain open indefinitely.
The GLP-1 NAION track's Daubert schedule will determine whether that injury category joins the viable litigation pool or joins a growing list of mass tort intake surges that did not survive general-causation scrutiny. Firms should not be committing significant resources to NAION intake until after the causation ruling. On the gastroparesis side, the same caution applies; the science is genuinely contested and the Daubert outcome is not predictable.
CPSC enforcement activity in 2026 has been elevated, with a record number of Class I recalls in the consumer products space. Plaintiff firms tracking product liability dockets should monitor CPSC recall databases; Class I recalls, which indicate a reasonable probability of serious injury or death, are a direct feed for design and warning defect cases that are worth evaluating before the defense moves to consolidate early cases into favorable MDL venues.
For ongoing coverage of MDL developments and industry news, see our industry news section. Analysis of the PFAS causation record and other mass tort expert issues is in our product liability coverage.